The clinical relevance of T cells in the control of a diverse set of human cancers is now
beyond doubt. However, the nature of the antigens that allow the immune system to …

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

The recent advent of methods for high-throughput single-cell molecular profiling has
catalyzed a growing sense in the scientific community that the time is ripe to complete the …

The immune system influences the fate of developing cancers by not only functioning as a
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …

Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …

Abstract 'T cell exhaustion'is a broad term that has been used to describe the response of T
cells to chronic antigen stimulation, first in the setting of chronic viral infection but more …